Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking

Friederike Braig, Anna Brandt, Mariele Goebeler, Hans-Peter Tony, Anna-Katharina Kurze, Peter Nollau, Thomas Bumm, Sebastian Böttcher, Ralf C. Bargou, Mascha Binder

Blood (2017) 129 (1): 100–104.

https://doi.org/10.1182/blood-2016-05-718395

Published: 2017

Includes: Supplemental data

Journal Articles

Pathogenesis-Based Development of Potential Mitigation Strategies for Blinatumomab-Associated Neurologic Events (NEs)

Matthias Klinger, PhD, Gerhard Zugmaier, MD, Virginie Naegele, PhD, Mariele Goebeler, MD, Christian Brandl, MS, Ralf C Bargou, MD, Peter Kufer, MD

Blood (2016) 128 (22): 1589.

https://doi.org/10.1182/blood.V128.22.1589.1589

Published: 2016

Journal Articles

Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma with the Bispecific T-Cell Engager (BiTE ® ) Antibody Construct Blinatumomab: Primary Analysis Results from an Open-Label, Phase 2 Study

Andreas Viardot, Mariele Goebeler, Georg Hess, Svenja Neumann, Michael Pfreundschuh, Nicole Adrian, Florian Zettl, Martin Libicher, Evelyn Degenhard, Julia Stieglmaier, Alicia Zhang, Dirk Nagorsen, Ralf C. Bargou

Blood (2014) 124 (21): 4460.

https://doi.org/10.1182/blood.V124.21.4460.4460

Published: 2014

Journal Articles

Open-Label Phase 2 Study Of The Bispecific T-Cell Engager (BiTE ® ) Blinatumomab In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Andreas Viardot, Mariele Goebeler, Michael Pfreundschuh, Nicole Adrian, Martin Libicher, Evelyn Degenhard, Julia Stieglmaier, Alicia Zhang, Dirk Nagorsen, Ralf C. Bargou

Blood (2013) 122 (21): 1811.

https://doi.org/10.1182/blood.V122.21.1811.1811

Published: 2013

Journal Articles

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomab

Matthias Klinger, Christian Brandl, Gerhard Zugmaier, Youssef Hijazi, Ralf C. Bargou, Max S. Topp, Nicola Gökbuget, Svenja Neumann, Mariele Goebeler, Andreas Viardot, Matthias Stelljes, Monika Brüggemann, Dieter Hoelzer, Evelyn Degenhard, Dirk Nagorsen, Patrick A. Baeuerle, Andreas Wolf, Peter Kufer

Blood (2012) 119 (26): 6226–6233.

https://doi.org/10.1182/blood-2012-01-400515

Published: 2012

Includes: Supplemental data

Journal Articles

Blinatumomab Monotherapy Shows Efficacy in Patients with Relapsed Diffuse Large B Cell Lymphoma

Blood (2011) 118 (21): 1637.

https://doi.org/10.1182/blood.V118.21.1637.1637

Published: 2011

Journal Articles

A Phase II Clinical Trial of the Anti-EGFR Antibody Cetuximab in Patients with Refractory or Relapsed Multiple Myeloma: Final Results,

Bastian von Tresckow, MD, Boris Böll, MD, Dennis A. Eichenauer, MD, Denissa Peine, Stefan Knop, MD, Mariele Goebeler, MD, Jens M. Chemnitz, MD, Michael Hallek, MD, Andreas Engert, MD, Kai Hübel, MD

Blood (2011) 118 (21): 3965.

https://doi.org/10.1182/blood.V118.21.3965.3965

Published: 2011

Journal Articles

CD19/CD3 Bispecific Antibody Blinatumomab (MT-103) Is Highly Effective In Treatment of Patients with Minimal Residual Disease From Chemotherapy-Resistant B-Precursor Acute Lymphoblastic Leukemia

Blood (2010) 116 (21): 174.

https://doi.org/10.1182/blood.V116.21.174.174

Published: 2010

Journal Articles

Treatment of Patients with Non-Hodgkin Lymphoma (NHL) with CD19/CD3 Bispecific Antibody Blinatumomab (MT103): Double-Step Dose Increase to Continuous Infusion of 60 μg/m 2 /d Is Tolerable and Highly Effective

Andreas Viardot, MD, Mariele Goebeler, MD, Jurgen S. Scheele, MD, PhD, Gerhard Zugmaier, MD, Richard Noppeney, MD, Stefan Knop, MD, Max S Topp, MD, Dirk Nagorsen, MD, Matthias Klinger, PhD, Margit Schmidt, PhD, Petra Klappers, Peter Kufer, MD, Hermann Einsele, MD, Ralf Bargou, MD

Blood (2010) 116 (21): 2880.

https://doi.org/10.1182/blood.V116.21.2880.2880

Published: 2010

Journal Articles

Confirmation of Safety, Efficacy and Response Duration in Non-Hodgkin Lymphoma Patients Treated with 60 μg/m 2 /d of BiTE® Antibody Blinatumomab.

Dirk Nagorsen, Gerhard Zugmaier, Andreas Viardot, Mariele Goebeler, Richard Noppeney, Margit Schmidt, Petra Klappers, Patrick A Baeuerle, Peter Kufer, Ralf C Bargou

Blood (2009) 114 (22): 2723.

https://doi.org/10.1182/blood.V114.22.2723.2723

Published: 2009

Journal Articles

Deferasirox (Exjade ® ) Treatment of Chelation-Naive and Pre-Chelated MDS Patients with Transfusional Iron-Overload in the Medical Practice:Results From the Observational Studies Extend and Exjange.

Norbert Gattermann, Oliver Leismann, Rudolf Schlag, Klaus Blumenstengel, Mariele Goebeler, Matthias Groschek, Christoph Losem, Maria Procaccianti, Sieglinde Stern, Alexia Nass, Ulrich Germing

Blood (2009) 114 (22): 3805.

https://doi.org/10.1182/blood.V114.22.3805.3805

Published: 2009

Journal Articles

Report of a Phase II Trial of Single-Agent BiTE® Antibody Blinatumomab in Patients with Minimal Residual Disease (MRD) Positive B-Precursor Acute Lymphoblastic Leukemia (ALL).

Blood (2009) 114 (22): 840.

https://doi.org/10.1182/blood.V114.22.840.840

Published: 2009

Journal Articles

Identification of a Predictive Factor for Reversible Neurological Adverse Events in a Subset of Non-Hodgkin Lymphoma Patients Treated with CD19-Specific BiTE ® Antibody Blinatumomab.

Gerhard Zugmaier, Dirk Nagorsen, Matthias Klinger, Ralf C Bargou, Mariele Goebeler, Andreas Viardot, Patrick A Baeuerle, Peter Kufer

Blood (2009) 114 (22): 4793.

https://doi.org/10.1182/blood.V114.22.4793.4793

Published: 2009

Journal Articles

Transient Laboratory Findings Upon First Dosing with T-Cell Engaging BiTE® Antibody Blinatumomab in Non-Hodgkin Lymphoma Patients.

Dirk Nagorsen, Gerhard Zugmaier, Peter Kufer, Matthias Klinger, Andreas Viardot, Mariele Goebeler, Margit Schmidt, Petra Klappers, Andreas Wolf, Christian Brandl, Patrick A Baeuerle, Ralf C Bargou

Blood (2009) 114 (22): 4798.

https://doi.org/10.1182/blood.V114.22.4798.4798

Published: 2009

Journal Articles

Sustained Response Duration Seen after Treatment with Single Agent Blinatumomab (MT103/MEDI-538) in the Ongoing Phase I Study MT103- 104 in Patients with Relapsed NHL

Ralf C Bargou, MD, Peter Kufer, MD, Mariele Goebeler, MD, Stefan Knop, MD, Hermann Einsele, MD, Richard Noppeney, MD, Andreas Viardot, MD, Patrick A Baeuerle, PhD, Carsten Reinhardt, MD, Margit Schmidt, PhD, Petra Klappers, Dirk Nagorsen, MD, Gerhard Zugmaier, MD

Blood (2008) 112 (11): 267.

https://doi.org/10.1182/blood.V112.11.267.267

Published: 2008

Journal Articles

The Anti-CD19 Bispecific T-Cell Engager (BiTE) MT103 (MEDI-538), Induces Dose-Dependent Complete and Partial Responses in Relapsed Non-Hodgkin Lymphoma (NHL): Phase I Study MT103-104.

Ralf C. Bargou, MD, Peter Kufer, PhD, Mariele Goebeler, MD, Stefan Knop, MD, Hermann Einsele, MD, Rudolf Noppeney, MD, Andreas Viardot, MD, Georg Hess, MD, Gert Riethmueller, PhD, Dirk Reitsma, MD, Eugen Leo, MD, Carsten Reinhardt, MD, Gerhard Zugmaier, MD

Blood (2007) 110 (11): 2557.

https://doi.org/10.1182/blood.V110.11.2557.2557

Published: 2007

NARROW

Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking

Pathogenesis-Based Development of Potential Mitigation Strategies for Blinatumomab-Associated Neurologic Events (NEs)

Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma with the Bispecific T-Cell Engager (BiTE ® ) Antibody Construct Blinatumomab: Primary Analysis Results from an Open-Label, Phase 2 Study

Open-Label Phase 2 Study Of The Bispecific T-Cell Engager (BiTE ® ) Blinatumomab In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell–engaging CD19/CD3-bispecific BiTE antibody blinatumomab

Blinatumomab Monotherapy Shows Efficacy in Patients with Relapsed Diffuse Large B Cell Lymphoma

A Phase II Clinical Trial of the Anti-EGFR Antibody Cetuximab in Patients with Refractory or Relapsed Multiple Myeloma: Final Results,

CD19/CD3 Bispecific Antibody Blinatumomab (MT-103) Is Highly Effective In Treatment of Patients with Minimal Residual Disease From Chemotherapy-Resistant B-Precursor Acute Lymphoblastic Leukemia

Treatment of Patients with Non-Hodgkin Lymphoma (NHL) with CD19/CD3 Bispecific Antibody Blinatumomab (MT103): Double-Step Dose Increase to Continuous Infusion of 60 μg/m 2 /d Is Tolerable and Highly Effective

Confirmation of Safety, Efficacy and Response Duration in Non-Hodgkin Lymphoma Patients Treated with 60 μg/m 2 /d of BiTE® Antibody Blinatumomab.

Deferasirox (Exjade ® ) Treatment of Chelation-Naive and Pre-Chelated MDS Patients with Transfusional Iron-Overload in the Medical Practice:Results From the Observational Studies Extend and Exjange.

Report of a Phase II Trial of Single-Agent BiTE® Antibody Blinatumomab in Patients with Minimal Residual Disease (MRD) Positive B-Precursor Acute Lymphoblastic Leukemia (ALL).

Identification of a Predictive Factor for Reversible Neurological Adverse Events in a Subset of Non-Hodgkin Lymphoma Patients Treated with CD19-Specific BiTE ® Antibody Blinatumomab.

Transient Laboratory Findings Upon First Dosing with T-Cell Engaging BiTE® Antibody Blinatumomab in Non-Hodgkin Lymphoma Patients.

Sustained Response Duration Seen after Treatment with Single Agent Blinatumomab (MT103/MEDI-538) in the Ongoing Phase I Study MT103- 104 in Patients with Relapsed NHL

The Anti-CD19 Bispecific T-Cell Engager (BiTE) MT103 (MEDI-538), Induces Dose-Dependent Complete and Partial Responses in Relapsed Non-Hodgkin Lymphoma (NHL): Phase I Study MT103-104.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only